Avastin Faces New Rival In Korea As Lynparza Approved
This article was originally published in PharmAsia News
Executive Summary
The launch of AstraZeneca's Lynparza, a targeted therapy for advanced ovarian cancer, in South Korea will give more treatment options for platinum-resistant ovarian cancer patients, but the first PARP inhibitor to be launched in the country will have to go up against well-established rival Avastin.